The expanding universe of neurotrophic factors: Therapeutic potential in aging and age-associated disorders

Current Pharmaceutical Design

Volumn 16, Issue 6, 2010, Pages 698-717

  Lanni, C ^a   Stanga, S ^a   Racchi, M ^a   Govoni, S ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Age associated disorders; Aging; Growth factor synthesis inducer; Mimetic peptides; Neurodegeneration; Neurotrophic factors

Indexed keywords

ARTEMIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; NEURTURIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; CELL DEATH; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEPRESSION; EPILEPSY; GENE THERAPY; GENERALIZED ANXIETY DISORDER; GLIA CELL; HUMAN; MAJOR DEPRESSION; MEMORY DISORDER; NERVE CELL; NERVE EXCITABILITY; NEUROPATHIC PAIN; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OLIGODENDROGLIA; PAIN; PANIC; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RESTLESS LEGS SYNDROME; RETINA MACULA DEGENERATION; RETINITIS PIGMENTOSA; REVIEW; VISUAL DISORDER; ANIMAL; BRAIN; DRUG EFFECTS; GENETICS; LONGEVITY; METABOLISM; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; PROCEDURES;

AGING; ANIMALS; BRAIN; GENETIC THERAPY; HUMANS; LONGEVITY; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES;

EID: 77950256736     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790883741     Document Type: Review

References (274)

1. Barnes CA, Foster TC, Rao G, McNaughton BL. Specificity of functional changes during normal brain aging. Ann NY Acad Sci 1991; 640: 80-85
2. Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol 2008; 3: 41-66.
3. Anderton BH. Changes in the ageing brain in health and disease. Philos Trans R Soc Lond B Biol Sci 1997; 352: 1781-1792
4. West MJ. Regionally specific loss of neurones in the aging human hippocampus. Neurobiol Aging 1993; 14: 287-293
5. Bertoni-Freddari C, Fattoretti P, Casoli T, Meier-Ruge W, Ulrich J. Morphological adaptive response of the synaptic junctional zones in the human dentate gyrus during aging and Alzheimer's disease. Brain Res 1990; 517: 69-75.
6. Masliah E, Mallory M, Hansen L, De Teresa R, Terry RD. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 1993; 43: 192-197
7. Zhang L, Ravipati A, Joseph J, Roth GS. Aging-related changes in rat striatal D2 receptor mRNA-containing neurons: a quantitative nonradioactive in situ hybridization study. J Neurosci 1995; 15: 1735-1740
8. Govoni S. Monoamines. In: Squire LR, Ed. Encyclopedia of Neuroscience. Oxford: Oxford Academic Press 2009; vol.5: pp. 931-937
9. Sibille E, Su J, Leman S, Le Guisquet AM, Ibarguen-Vargas Y, Joeyen-Waldorf J, et al. Lack of serotonin1B receptor expression leads to age-related motor dysfunction, early onset of brain molecular aging and reduced longevity. Mol Psychiatry 2007; 12: 1042-1056
10. Jin LW, Saitoh T. Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy. Drugs Aging 1995; 6: 136-149
11. Mattson MP. Calcium as sculptor and destroyer of neural circuitry. Exp Gerontol 1992; 27: 29-49.
12. Gant JC, Sama MM, Landfield PW, Thibault O. Early and simultaneous emergence of multiple hippocampal biomarkers of aging is mediated by Ca2+-induced Ca2+ release. J Neurosci 2006; 26: 3482-3490
13. Lee CK, Weindruch R, Prolla TA. Gene-expression profile of the ageing brain in mice. Nat Genet 2000; 25: 294-297
14. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, et al. Gene regulation and DNA damage in the ageing human brain. Nature 2004; 429: 883-891
15. Miller JA, Oldham MC, Geschwind DH. A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. J Neurosci 2008; 28: 1410-1420
16. Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC, et al. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci 2003; 23: 3807-3819
17. Brooks WM, Lynch PJ, Ingle CC, Hatton A, Emson PC, Faull RL, et al. Gene expression profiles of metabolic enzyme transcripts in Alzheimer's disease. Brain Res 2007; 1127: 127-135
18. Keller JN, Gee J, Ding Q. The proteasome in brain aging. Ageing Res Rev 2002; 1: 279-293
19. Mattson MP, Lindvall O. Neurotrophic factor and cytokine signaling in the aging brain. In: Mattson MP, Geddes JW, Ed. The Aging Brain. Greenwich, CT: JAI 1997; pp. 299-345.
20. Zampieri N, Chao MV. Mechanisms of neurotrophin receptor signalling. Biochem Soc Trans 2006; 34: 607-611
21. Levy YS, Gilgun-Sherki Y, Melamed E, Offen D. Therapeutic potential of neurotrophic factors in neurodegenerative diseases. Bio Drugs 2005; 19: 97-127.
22. Tabuchi A. Synaptic plasticity-regulated gene expression: a key event in the long-lasting changes of neuronal function. Biol Pharm Bull 2008; 31: 327-335
23. Nabeshima T, Yamada K. Neurotrophic factor strategies for the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2000; 14: S39-S46.
24. Dawbarn D, Allen SJ. Neurotrophins and neurodegeneration. Neuropathol Appl Neurobiol 2003; 29: 211-230
25. Covaceuszach S, Capsoni S, Ugolini G, Spirito F, Vignone D, Cattaneo A. Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr Alzheimer Res 2009; 6:158-170
26. Cole GM, Frautschy SA. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. Exp Gerontol 2007; 42: 10-21.
27. Gasparini L, Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci 2003; 26: 404-406
28. Zuccato C, Marullo M, Conforti P, MacDonald ME, Tartari M, Cattaneo E. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol 2008; 18: 225-238
29. Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann NY Acad Sci 2008; 1144: 97-112.
30. Acharya MM, Hattiangady B, Shetty AK. Progress in neuroprotective strategies for preventing epilepsy. Prog Neurobiol 2008; 84: 363-404.
31. Lai KO, Glass DJ, Geis D, Yancopoulos GD, Ip NY. Structural determinants of Trk receptor specificities using BDNF-based neurotrophin chimeras. J Neurosci Res 1996; 46: 618-629
32. Bibel M, Barde YA. Neurotrophin signal transduction in the nervous system. Genes Dev 2000; 14: 2919-2957
33. Munck Petersen C, Nielsen MS, Jacobsen C, Tauris J, Jacobsen L, Gliemann J, et al. Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding. EMBO J 1999; 18: 595-604.
34. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature 2004; 427: 843-848
35. Teng HK, Teng KK, Lee R, Wright S, Tevar S, Almeida RD, et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci 2005; 25: 5455-5463
36. Pitts AF, Miller MW. Expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 in the somatosensory cortex of the mature rat: coexpression with high-affinity neurotrophin receptors. J Comp Neurol 2000; 418: 241-254
37. Giacobini E. Cholinesterase in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorder's. In: Giacobini E, Pepeu G, Ed. The Brain Cholinergic System in Health and Disease. Informa Healthcare 2006; pp. 235-264
38. Culmsee C, Gerling N, Lehmann M, Nikolova-Karakashian M, Prehn JH, Mattson MP, et al. Nerve growth factor survival signaling in cultured hippocampal neurons is mediated through TrkA and requires the common neurotrophin receptor P75. Neuroscience 2002; 115: 1089-1108
39. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001; 24: 1217-1281
40. Fischer W, Wictorin K, Bjorklund A, Williams LR, Varon S, Gage FH. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987; 329: 65-68
41. Fischer W. Nerve growth factor reverses spatial memory impairments in aged rats. Neurochem Int 1994; 25: 47-52.
42. Mobley WC, Rutkowski JL, Tennekoon GI, Gemski J, Buchanan K, Johnston MV. Nerve growth factor increases choline acetyltransferase activity in developing basal forebrain neurons. Brain Res 1986; 387: 53-62.
43. Hellweg R, von Richthofen S, Anders D, Baethge C, Röpke S, Hartung HD, et al. The time course of nerve growth factor content in different neuropsychiatric diseases - a unifying hypothesis. J Neural Transm 1998; 105: 871-903.
44. Svendsen CN, Cooper JD, Sofroniew MV. Trophic factor effects on septal cholinergic neurons. Ann NY Acad Sci 1991; 640: 91-94
45. Martinez HJ, Dreyfus CF, Jonkait GM, Black IB. Nerve growth factor selectively increases cholinergic markers but not neuropeptides in rat basal forebrain culture. Brain Res 1987; 412: 295-301.
46. Bergado JA, Fernández CI, Gómez-Soria A, González O. Chronic intraventricular infusion with NGF improves LTP in old cognitively-impaired rats. Brain Res 1997; 770: 1-9.
47. Tuszynski MH, Sang H, Yoshida K, Gage FH. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol 1991; 30: 625-636
48. Kasa P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer's disease. Prog Neurobiol 1997; 52: 511-535
49. Gibbs RB. Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function. Exp Neurol 1998; 151: 289-302.
50. Crowley C, Spencer SD, Nishimura MC, Chen KS, Pitts-Meek S, Armanini MP, et al. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 1994; 76: 1001-1011
51. Mufson EJ, Ma SY, Dills J, Cochran EJ, Leurgans S, Wuu J, et al. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 2002; 443: 136-153
52. Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol 2004; 56: 520-531
53. Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in antinerve growth factor mice. Proc Natl Acad Sci USA 2002; 99: 12432-12437
54. Cuello AC, Bruno MA, Bell KF. NGF-cholinergic dependency in brain aging, MCI and Alzheimer's disease. Curr Alzheimer Res 2007; 4: 351-358
55. Schulte-Herbrüggen O, Jockers-Scherübl MC, Hellweg R. Neurotrophins: from pathophysiology to treatment in Alzheimer's disease. Curr Alzheimer Res 2008; 5: 38-44.
56. Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev 2000; 33: 199-227.
57. Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 2000; 57: 846-851
58. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 1995; 15: 6213-6221
59. Salehi A, Delcroix JD, Mobley WC. Traffic at the intersection of neurotrophic factor signaling and neurodegeneration. Trends Neurosci 2003; 26: 73-80.
60. Tuszynski MH, Blesch A. Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease. Prog Brain Res 2004; 146: 441-449
61. Ibanez CF. Jekyll-Hyde neurotrophins: the story of proNGF. Trends Neurosci 2002; 25: 284-286
62. Fahnestock M, Yu G, Michalski B, Mathew S, Colquhoun A, Ross GM, et al. The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. J Neurochem 2004; 89: 581-592
63. Al-Shawi R, Hafner A, Chun S, Raza S, Crutcher K, Thrasivoulou C, et al. ProNGF, sortilin, and age-related neurodegeneration. Ann NY Acad Sci 2007; 1119: 208-215
64. Lorigados L, Pavón N, Serrano T, Robinson MA. Nerve growth factor and neurological diseases. Rev Neurol 1998; 26: 744-748
65. Stuerenburg HJ, Kunze K. Tissue nerve growth factor concentrations in neuromuscular diseases. Eur J Neurol 1998; 5: 487-490
66. Kust BM, Copray JC, Brouwer N, Troost D, Boddeke HW. Elevated levels of neurotrophins in human biceps brachii tissue of amyotrophic lateral sclerosis. Exp Neurol 2002; 177: 419-427
67. Jankowsky JL, Patterson PH. The role of cytokines and growth factors in seizures and their sequelae. Prog Neurobiol 2001; 63: 125-149
68. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-555
69. Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9: 246-257
70. Tuszynski MH, Roberts J, Senut MC, U HS, Gage FH. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther 1996; 3: 305-314
71. Tuszynski MH. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2007; 21: 179-189
72. Longo FM, Massa SM. Neurotrophin-based strategies for neuroprotection. J Alzheimers Dis 2004; 6: S13-S7.
73. Massa SM, Xie Y, Longo FM. Alzheimer's therapeutics: neurotrophin domain small molecule mimetics. J Mol Neurosci 2003; 20: 323-326
74. Xie Y, Tisi MA, Yeo TT, Longo FM. Nerve growth factor (NGF) loop 4 dimeric mimetics activate ERK and AKT and promote NGF-like neurotrophic effects. J Biol Chem 2000; 275: 29868-29874
75. Colangelo AM, Bianco MR, Vitagliano L, Cavaliere C, Cirillo G, De Gioia L, et al. A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. J Neurosci 2008; 28: 2698-2709
76. Ruiz G, Ceballos D, Banos JE. Behavioral and histological effects of endoneurial administration of nerve growth factor: possible implications in neuropathic pain. Brain Res 2004; 1011: 1-6.
77. Grundman M, Capparelli E, Kim HT, Morris JC, Farlow M, Rubin EH, et al. A multicenter, randomized, placebo controlled, multipledose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sci 2003; 73: 539-553
78. Hayashida M, Fukuda K, Fukunaga A. Clinical application of adenosine and ATP for pain control. J Anesth 2005; 19: 225-235
79. Lee FS, Chao MV. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc Natl Acad Sci USA 2001; 98: 3555-3560
80. Crook TH, Ferris SH, Alvarez XA, Laredo M, Moessler H. Effects of N-PEP-12 on memory among older adults. Int Clin Psychopharmacol 2005; 20: 97-100.
81. Veziers J, Lesourd M, Jollivet C, Montero-Menei C, Benoit JP, Menei P. Analysis of brain biocompatibility of drug-releasing biodegradable microspheres by scanning and transmission electron microscopy. J Neurosurg 2001; 95: 489-494
82. Wang ZF, Tang LL, Yan H, Wang YJ, Tang XC. Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol Biochem Behav 2006; 83: 603-611
83. Xaliproden: SR 57746, SR 57746A, xaliproden hydrochloride, xaliprodene. Drugs R D 2003; 4: 386-388
84. Semkova I, Wolz P, Schilling M, Krieglstein J. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur J Pharmacol 1996; 315: 19-30.
85. Mandel S, Weinreb O, Amit T, Youdim MB. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 2005; 48: 379-387
86. Heese K, Otten U, Mathivet P, Raiteri M, Marescaux C, Bernasconi R. GABA(B) receptor antagonists elevate both mRNA and protein levels of the neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) but not neurotrophin-3 (NT-3) in brain and spinal cord of rats. Neuropharmacology 2000; 39: 449-462
87. Toyomotoa M, Inouea S, Ohtab K, Kunoc S, Ohtad M, Hayashia K, et al. Production of NGF, BDNF and GDNF in mouse astrocyte cultures is strongly enhanced by a cerebral vasodilator, ifenprodil. Neurosci Lett 2005; 379; 185-189
88. Mazella J, Vincent JP. Functional roles of the NTS2 and NTS3 receptors. Peptides 2006; 27: 2469-2475
89. Rosenthal A, Goeddel DV, Nguyen T, Martin E, Burton LE, Shih A, et al. Primary structure and biological activity of human brain-derived neurotrophic factor. Endocrinology 1991; 129: 1289-1294
90. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde Y-A. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 1990; 9: 2459-2464
91. Mufson EJ, Kroin JS, Sendera TJ, Sobreviela T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 1999; 57: 451-484
92. Schecterson LC, Bothwell M. Novel roles for neurotrophins are suggested by BDNF and NT-3 mRNA expression in developing neurons. Neuron 1992; 9: 449-463
93. Katoh-Semba R, Takeguchi IK, Semba R, Kato K. Distribution of brain-derived neurotrophic factor in rats and its changes with development in the brain. J Neurochem 1997; 69: 34-42.
94. Lee J, Duan W, Mattson MP. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem 2002; 82: 1367-1375
95. Oliff HS, Berchtold NC, Isackson P, Cotman CW. Exercise-induced regulation of brain-derived neurotrophic factor (BDNF) transcripts in the rat hippocampus. Mol Brain Res 1998; 61: 147-153
96. Young D, Lawlor PA, Leone P, Dragunow M, During MJ. Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nat Med 1999; 5: 448-453
97. Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004; 306: 487-491
98. Bekinschtein P, Cammarota M, Igaz LM, Bevilaqua LR, Izquierdo I, Medina JH. Persistence of long-term memory storage requires a late protein synthesis- and BDNF- dependent phase in the hippocampus. Neuron 2007; 53: 261-277
99. Gooney M, Messaoudi E, Maher FO, Bramham CR, Lynch MA. BDNF-induced LTP in dentate gyrus is impaired with age: analysis of changes in cell signaling events. Neurobiol Aging 2004; 25: 1323-1331
100. Croll SD, Ip NY, Lindsay RM, Wiegand SJ. Expression of BDNF and trkB as a function of age and cognitive performance. Brain Res 1998; 812: 200-208
101. Pelleymounter MA, Cullen MJ, Baker MB, Gollub M, Wellman C. The effects of intrahippocampal BDNF and NGF on spatial learning in aged Long Evans rats. Mol Chem Neuropathol 1996; 29: 211-226
102. Morís G, Vega JA. Neurotrophic factors: basis for their clinical application. Neurologia 2003; 18: 18-28.
103. Askanas V. Neurotrophic factors and amyotrophic lateral sclerosis. Adv Neurol 1995; 68: 241-244
104. Erickson JT, Brosenitsch TA, Katz DM. Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor are required simultaneously for survival of dopaminergic primary sensory neurons in vivo. J Neurosci 2001; 21: 581-589
105. Alberch J, Pérez-Navarro E, Canals JM. Neurotrophic factors in Huntington's disease. Prog Brain Res 2004; 146: 195-229.
106. Knipper M, da Penha Berzaghi M, Blöchl A, Breer H, Thoenen H, Lindholm D. Positive feedback between acetylcholine and the neurotrophins nerve growth factor and brain-derived neurotrophic factor in the rat hippocampus. Eur J Neurosci 1994; 6: 668-671
107. Auld DS, Mennicken F, Day JC, Quirion R. Neurotrophins differentially enhance acetylcholine release, acetylcholine content and choline acetyltransferase activity in basal forebrain neurons. J Neurochem 2001; 77: 253-262
108. Allen SJ, Wilcock GK, Dawbarn D. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease. Biochem Biophys Res Commun 1999; 264: 648-651
109. Murer MG, Boissiere F, Yan Q, Hunot S, Villares J, Faucheux B, et al. An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease. Neuroscience 1999; 88: 1015-1032
110. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol 2000; 166: 127-135
111. von Bohlen und Halbach O, Minichiello L, Unsicker K. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra. FASEB J 2005; 19: 1740-1742
112. Mutoh T, Sobue G, Hamano T, Kuriyama M, Hirayama M, Yamamoto M, et al. Decreased phosphorylation levels of TrkB neurotrophin receptor in the spinal cords from patients with amyotrophic lateral sclerosis. Neurochem Res 2000; 25: 239-245
113. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001; 293: 493-498
114. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-7547
115. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-265
116. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160: 1516-1518
117. Pollak DD, Monje FJ, Zuckerman L, Denny CA, Drew MR, Kandel ER. An animal model of a behavioral intervention for depression. Neuron 2008; 60: 149-161
118. Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors 2004; 22: 123-131
119. Lähteinen S, Pitkänen A, Saarelainen T, Nissinen J, Koponen E, Castrén E. Decreased BDNF signalling in transgenic mice reduces epileptogenesis. Eur J Neurosci 2002; 15: 721-734
120. Croll SD, Suri C, Compton DL, Simmons MV, Yancopoulos GD, Lindsay RM, et al. Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex. Neuroscience 1999; 93: 1491-1506
121. Scharfman HE, Goodman JH, Sollas AL, Croll SD. Spontaneous limbic seizures after intrahippocampal infusion of brain-derived neurotrophic factor. Exp Neurol 2002; 174: 201-214
122. Malcangio M, Lessmann V. A common thread for pain and memory synapses? Brain-derived neurotrophic factor and trkB receptors. Trends Pharmacol Sci 2003; 24: 11621.
123. Fukuoka T, Kondo E, Dai Y, Hashimoto N, Noguchi K. Brain-derived neurotrophic factor increases in the uninjured dorsal root ganglion neurons in selective spinal nerve ligation model. J Neurosci 2001; 21: 4891-4900
124. Pezet S, Malcangio M, Lever IJ, Perkinton MS, Thompson SW, Williams RJ, et al. Noxious stimulation induces Trk receptor and downstream ERK phosphorylation in spinal dorsal horn. Mol Cell Neurosci 2002; 21: 684-695
125. Tuszynski MH. Gene therapy for neurological disease. Expert Opin Biol Ther 2003; 3: 815-828
126. Loh NK, Woerly S, Bunt SM, Wilton SD, Harvey AR. The regrowth of axons within tissue defects in the CNS is promoted by implanted hydrogel matrices that contain BDNF and CNTF producing fibroblasts. Exp Neurol 2001; 170: 72-84.
127. A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF Study Group (Phase III). Neurology 1999; 52: 1427-1433
128. Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 201-206
129. Turner MR, Parton MJ, Leigh PN. Clinical trials in ALS: an overview. Semin Neurol 2001; 21: 167-175
130. O'Leary PD, Hughes RA. Design of potent peptide mimetics of brain-derived neurotrophic factor. J Biol Chem 2003; 278: 25738-25744
131. Fletcher JM, Morton CJ, Zwar RA, Murray SS, O'Leary PD, Hughes RA. Design of a conformationally defined and proteolytically stable circular mimetic of Brain-derived Neurotrophic Factor. J Biol Chem 2008; 283: 33375-33383
132. Price RD, Milne SA, Sharkey J, Matsuoka N. Advances in small molecules promoting neurotrophic function. Pharmacol Ther 2007; 115: 292-306.
133. Marvanová M, Lakso M, Pirhonen J, Nawa H, Wong G, Castrén E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci 2001; 18: 247-258
134. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001; 411: 86-89
135. Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S, El ReFaey H, et al. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 2006; 7: 1513-1529
136. Du F, Li R, Huang Y, Li X, Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 2005; 22: 2422-2430
137. Guo H, Tang Z, Yu Y, Xu L, Jin G, Zhou J. Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures. Eur J Neurosci 2002; 16: 1861-1870
138. Tobe EH. Transdermal selegiline: new opportunity for managing depression. J Am Osteopath Assoc 2008; 108: 85-86
139. Froestl W, Gallagher M, Jenkins H, Madrid A, Melcher T, Teichman S, et al. SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol 2004; 68: 1479-1487
140. Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T, et al. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics 2009; 6: 163-174
141. Weinreb O, Amit T, Bar-Am O, Youdim MB. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann NY Acad Sci 2007; 1122: 155-168
142. O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets 2007; 8: 603-620
143. Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry 2001; 178: 200-206
144. Gold BG, Villafranca JE. Neuroimmunophilin ligands: the development of novel neuroregenerative/neuroprotective compounds. Curr Top Med Chem 2003; 3: 1368-1375
145. Tanaka K, Fujita N, Ogawa N. Immunosuppressive (FK506) and non-immunosuppressive (GPI1046) immunophilin ligands activate neurotrophic factors in the mouse brain. Brain Res 2003; 970: 250-253
146. Hong Z, Wang G, Gu J, Pan J, Bai L, Zhang S, et al. Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice. Eur J Neurosci 2007; 26: 1500-1508
147. Lapchak PA, Jiao S, Miller PJ, Williams LR, Cummins V, Inouye G, et al. Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Cell Tissue Res 1996; 286: 179-189
148. Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 1999; 11: 1554-1566
149. Milbrandt J, de Sauvage FJ, Fahrner TJ, Baloh RH, Leitner ML, Tansey MG, et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 1998; 20: 245-253
150. Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 1998; 21: 1291-1302
151. Airaksinen MS, Holm L, Hatinen T. Evolution of the GDNF family ligands and receptors. Brain Behav Evol 2006; 68: 181-190
152. Bespalov MM, Saarma M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 2007; 28: 68-74.
153. Oo TF, Ries V, Cho J, Kholodilov N, Burke RE. Anatomical basis of glial cell line-derived neurotrophic factor expression in the striatum and related basal ganglia during postnatal development of the rat. J Comp Neurol 2005; 484: 57-67.
154. Springer JE, Mu X, Bergmann LW, Trojanowski JQ. Expression of GDNF mRNA in rat and human nervous tissue. Exp Neurol 1994; 127: 167-170
155. Bär KJ, Saldanha GJ, Kennedy AJ, Facer P, Birch R, Carlstedt T, et al. GDNF and its receptor component Ret in injured human nerves and dorsal root ganglia. Neuroreport 1998; 9: 43-47
156. Coulpier M, Ibáñez CF. Retrograde propagation of GDNF-mediated signals in sympathetic neurons. Mol Cell Neurosci 2004; 27: 132-139
157. Besset V, Scott RP, Ibáñez CF. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J Biol Chem 2000; 275: 39159-39166
158. Sawada H, Ibi M, Kihara T, Urushitani M, Nakanishi M, Akaike A, et al. Neuroprotective mechanism of glial cell line-derived neurotrophic factor in mesencephalic neurons. J Neurochem 2000; 74: 1175-1184
159. Mijatovic J, Airavaara M, Planken A, Auvinen P, Raasmaja A, Piepponen TP, et al. Constitutive Ret activity in knock-in multiple endocrine neoplasia type B mice induces profound elevation of brain dopamine concentration via enhanced synthesis and increases the number of TH-positive cells in the substantia nigra. J Neurosci 2007; 27: 4799-4809
160. Paratcha G, Ledda F, Ibáñez CF. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 2003; 113: 867-879
161. Popsueva A, Poteryaev D, Arighi E, Meng XJ, Angers-Loustau A, Kaplan D, et al. GDNF promotes tubulogenesis of GFR alpha 1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase. J Cell Biol 2003; 161: 119-129
162. Bourque MJ, Trudeau LE. GDNF enhances the synaptic efficacy of dopaminergic neurons in culture. Eur J Neurosci 2000; 12; 3172-3180
163. Ledda F, Paratcha G, Sandoval-Guzman T, Ibáñez CF. GDNF and GFRα1 promote formation of neuronal synapses by ligand-induced cell adhesion. Nat Neurosci 2007; 10: 293-300.
164. Ai Y, Markesbery W, Zhang Z, Grondin R, Elseberry D, Gerhardt GA, et al. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol 2003; 461: 250-261
165. Grondin R, Cass WA, Zhang Z, Stanford JA, Gash DM, Gerhardt GA. Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J Neurosci 2003; 23: 1974-1980
166. Grondin R, Zhang Z, Yi A, Cass WA, Maswood N, Andersen AH, et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002; 125: 2191-2201
167. Hurelbrink CB, Barker RA. The potential of GDNF as a treatment for Parkinson's disease. Exp Neurol 2004; 185: 1-6.
168. Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994; 266: 1062-1064
169. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell linederived neurotrophic factor in Parkinson disease. Nat Med 2003; 9: 589-595
170. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005; 102: 216-222
171. Isacson O, Kordower JH. Future of cell and gene therapies for Parkinson's disease. Ann Neurol 2008; 2: S122-38.
172. Hong M, Mukhida K, Mendez I. GDNF therapy for Parkinson's disease. Expert Rev Neurother 2008; 8: 1125-1139
173. Behrstock S, Ebert A, McHugh J, Vosberg S, Moore J, Schneider B, et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther 2006; 13: 379-388
174. Tokugawa K, Yamamoto K, Nishiguchi M, Sekine T, Sakai M, Ueki T, et al. XIB4035, a novel nonpeptidyl small molecule agonist for GFRα-1. Neurochem Int 2003; 42: 81-86
175. Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, et al. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J 2008; 22: 2488-2497
176. Saavedra A, Baltazar G, Duarte EP. Driving GDNF expression: the green and the red traffic lights. Prog Neurobiol 2008; 86: 186-215.
177. Ohta K, Kuno S, Mizuta I, Fujinami A, Matsui H, Ohta M. Effects of
178. Saavedra A, Baltazar G, Santos P, Carvalho CM, Duarte EP. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol Dis 2006; 23: 533-542
179. Caumont AS, Octave JN, Hermans E. Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells. Neurosci Lett 2006; 394: 196-201.
180. Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Kuno S. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett 2001; 310: 117-120
181. Hisaoka K, Takebayashi M, Tsuchioka M, Maeda N, Nakata Y, Yamawaki S. Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells. J Pharmacol Exp Ther 2007; 321: 148-157
182. Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Creedon DJ, Johnson EM, Jr, et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 1996; 384: 467-470
183. Li H, He Z, Su T, Ma Y, Lu S, Dai C, et al. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease. Neurol Res 2003; 25: 263-267
184. Oiwa Y, Yoshimura R, Nakai K, Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res 2002; 947: 271-283
185. Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell J, 3rd, Gasmi M, et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP treated monkeys. Ann Neurol 2006; 60: 706-715
186. Herzog CD, Dass B, Holden JE, Stansell J, 3rd, Gasmi M, Tuszynski MH, et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 2007; 22: 1124-1132
187. Sah DW, Ossipov MH, Rossomando A, Silvian L, Porreca F. New approaches for the treatment of pain: the GDNF family of neurotrophic growth factors. Curr Top Med Chem 2005; 5: 577-583
188. Murphy M, Dutton R, Koblar S, Cheema S, Bartlett P. Cytokines which signal through the LIF receptor and their actions in the nervous system. Prog Neurobiol 1997; 52: 355-378
189. Nakashima K, Wiese S, Yanagisawa M, Arakawa H, Kimura N, Hisatsune T, et al. Developmental requirement of gp130 signaling in neuronal survival and astrocyte differentiation. J Neurosci 1999; 19: 5429-5434
190. Horton AR, Barlett PF, Pennica D, Davies AM. Cytokines promote the survival of mouse cranial sensory neurones at different developmental stages. Eur J Neurosci 1998; 10: 673-679
191. Barbin G, Manthorpe M, Varon S. Purification of the chick eye ciliary neuronotrophic factor. J Neurochem 1984; 43: 1468-1478
192. Curtis R, Adryan KM, Zhu Y, Harkness PJ, Lindsay RM, Di Stefano PS. Retrograde axonal transport of ciliary neurotrophic factor is increased by peripheral nerve injury. Nature 1993; 365: 253-255
193. Sendtner M, Dittrich F, Hughes RA, Thoenen H. Actions of CNTF and neurotrophins on degenerating motoneurons: preclinical studies and clinical implications. J Neurol Sci 1994; 124: S77-S83.
194. Lindsay RM. Neurotrophic growth factors and neurodegenerative diseases: therapeutic potential of the neurotrophins and ciliary neurotrophic factor. Neurobiol Aging 1994; 15: 249-251
195. Sleeman MW, Anderson KD, Lambert PD, Yancopoulos GD, Wiegand SJ. The ciliary neurotrophic factor and its receptor, CNTFR alpha. Pharma Acta Helv 2000; 74: 265-272
196. Ip NY, Yancopoulos GD. The neurotrophins and CNTF: two families of collaborative neurotrophic factors. Annu Rev Neurosci 1996; 19: 491-515.
197. Peterson WM, Wang Q, Tzekova R, Wiegand SJ. Ciliary neurotrophic factor and stress stimuli activate the Jak-STAT pathway in retinal neurons and glia. J Neurosci 2000; 20: 4081-4090
198. Hashimoto Y, Abiru Y, Nishio C, Hatanaka H. Synergistic effects of brain-derived neurotrophic factor and ciliary neurotrophic factor on cultured basal forebrain cholinergic neurons from postnatal 2-week-old rats. Brain Res Dev Brain Res 1999; 115: 25-32.
199. Mori M, Jefferson JJ, Garbe DS. CNTF: A putative link between dopamine D2 receptors and neurogenesis. J Neurosci 2008; 28: 5867-5869
200. Yang P, Arnold SA, Habas A, Hetman M, Hagg T. Ciliary neurotrophic factor mediates dopamineD2 receptor-induced CNS neurogenesis in adult mice. J Neurosci 2008; 28: 2231-2241
201. Bloch J, Bachoud-Lévi AC, Déglon N, Lefaucheur JP, Winkel L, Palfi S, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004; 15: 968-975
202. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006; 103: 3896-3901
203. Emerich DF, Thanos CG. Intracompartmental delivery of CNTF as therapy for Huntinton's disease and retinitis pigmentosa. Curr Gene Ther 2006; 6: 147-159
204. Beltran WA. On the role of CNTF as a potential therapy for retinal degeneration: Dr. Jekyll or Mr. Hyde? Adv Exp Med Biol 2008; 613: 45-51.
205. Vardatsikos G, Sahu A, Srivastava A. The insulin-like growth factor family: Molecular mechanisms, redox regulation and clinical implications. Antioxid Redox Signal 2009; 5: 1165-1190
206. De Keyser J, Wilczak N, De Backer JP, Herroelen L, Vauquelin G. Insulin-like growth factor-I receptors in human brain and pituitary gland: an autoradiographic study. Synapse 1994; 17: 196-202.
207. Quesada A, Romeo HE, Micevych P. Distribution and localization patterns of estrogen receptor-β and insulin-like growth factor-1 receptors in neurons and glial cells of the female rat substantia nigra: localization of ERβ and IGF-1R in substantia nigra. J Comp Neurol 2007; 503: 198-208.
208. Werner H, Weinstein D, Bentov I. Similarities and differences between insulin and IGF-I: Structures, receptors, and signalling pathways. Arch Physiol Biochem 2008; 114: 17-22.
209. Froesch ER, Zapf J. Insulin-like growth factors and insulin: comparative aspects. Diabetologia 1985; 28: 485-493
210. Li Y, Wu H, Khardori R, Song YH, Lu YW, Geng YJ. Insulin-like growth factor-1 receptor activation prevents high glucose-induced mitochondrial dysfunction, cytochrome-c release and apoptosis. Biochem Biophys Res Commun 2009; 384: 259-264
211. Sievers C, Schneider HJ, Stalla GK. Insulin-like growth factor-1 in plasma and brain: regulation in health and disease. Front Biosci 2008; 13: 85-99.
212. Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling pathway. Curr Pharm Des 2007; 13: 663-669
213. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
214. Bateman JM, McNeill H. Insulin/IGF signalling in neurogenesis. Cell Mol Life Sci 2006; 63: 1701-1705
215. Broughton S, Alic N, Slack C, Bass T, Ikeya T, Vinti G, et al. Reduction of DILP2 in Drosophila triages a metabolic phenotype from lifespan revealing redundancy and compensation among DILPs. PLoS One 2008; 3: e3721.
216. Carro E, Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 2004; 490: 127-133
217. Solano DC, Sironi M, Bonfini C, Solerte SB, Govoni S, Racchi M. Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J 2000; 14:1015-1022
218. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, et al. Stimulation of β-amyloid precursor protein trafficking by insulin reduces intraneuronal β-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001; 21: 2561-2570
219. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-β levels. Nat Med 2002; 8: 1390-1397
220. Lesort M, Johnson GVW. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience 2000; 99: 305-316
221. Araki W, Kume H, Oda A, Tamaoka A, Kametani F. IGF-1 promotes β-amyloid production by a secretase-independent mechanism. Biochem Biophys Res Commun 2009; 380: 111-114
222. Wang JY, Grabacka M, Marcinkiewicz C, Staniszewska I, Peruzzi F, Khalili K, et al. Involvement of α1β1 integrin in insulin-like growth factor-1-mediated protection of PC12 neuronal processes from tumor necrosis factor-α-induced injury. J Neurosci Res 2006; 83: 7-18.
223. Aberg MA, Aberg ND, Hedbäcker H, Oscarsson J, Eriksson PS. Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J Neurosci 2000; 20: 2896-2903
224. http://clinicaltrials.gov
225. Murialdo G, Barreca A, Nobili F, Rollero A, Timossi G, Gianelli MV, et al. Relationships between cortisol, dehydroepiandrosterone sulphate and insulin-like growth factor-I system in dementia. J Endocrinol Invest 2001; 24: 139-146
226. Carpino PA, Lefker BA, Toler SM, Pan LC, Hadcock JR, Cook ER, et al. Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs). Discovery of capromorelin. Bioorg Med Chem 2003; 11: 581-590
227. Pan LC, Carpino PA, Lefker BA, Ragan JA, Toler SM, Pettersen JC, et al. Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine growth hormone secretagogue. Endocrine 2001; 14: 121-132
228. Thompson DD. Aging and sarcopenia. J Musculoskelet Neuronal Interact 2007; 7: 344-345
229. Loddick SA, Liu XJ, Lu ZX, Liu C, Behan DP, Chalmers DC, et al. Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. Proc Natl Acad Sci USA 1998; 95: 1894-1898
230. Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Adv Ther 2009; 26: 40-54.
231. Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008; 71: 1770-1775
232. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301: 839-842
233. Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006; 67; 20-27
234. Otten U, Ehrhard P, Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci USA 1989; 86: 10059-10063
235. Lee HW, Na YJ, Jung PK, Kim MN, Kim SM, Chung JS, et al. Nerve growth factor stimulates proliferation, adhesion and thymopoietic cytokine expression in mouse thymic epithelial cells in vitro. Regul Pept 2008; 147: 72-81.
236. Samah B, Porcheray F, Gras G. Neurotrophins modulate monocyte chemotaxis without affecting macrophage function. Clin Exp Immunol 2008; 151: 476-486
237. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WEF, et al. Activated human T cells, B cells, and monocytes produce brainderived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999; 189: 865-870
238. Laurenzi MA, Beccari T, Stenke L, Sjolinder M, Stinchi S, Lindgren JA. Expression of mRNA encoding neurotrophins and neurotrophin receptors in human granulocytes and bone marrow cells - enhanced neurotrophin-4 expression induced by LTB4. J Leukoc Biol 1998; 64: 228-234
239. Tam SY, Tsai M, Yamaguchi M, Yano K, Butterfield JH, Galli SJ. Expression of functional TrkA receptor tyrosine kinase in the HMC-1 human mast cell line and in human mast cells. Blood 1997; 90: 1807-1820
240. Raap U, Deneka N, Bruder M, Kapp A, Wedi B. Differential upregulation of neurotrophin receptors and functional activity of neurotrophins on peripheral blood eosinophils of patients with allergic rhinitis, atopic dermatitis and nonatopic subjects. Clin Exp Allergy 2008; 38: 1493-1498
241. Nassenstein C, Braun A, Erpenbeck VJ, Lommatzsch M, Schmidt S, Krug N, et al. The neurotrophins nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 are survival and activation factors for eosinophils in patients with allergic bronchial asthma. J Exp Med 2003; 198: 455-467
242. Dittrich F, Thoenen H, Sendtner M. Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat. Ann Neurol 1994; 35: 151-163
243. Kuhlmann T, Remington L, Cognet I, Bourbonniere L, Zehntner S, Guilhot F, et al. Continued administration of ciliary neurotrophic factor protects mice from inflammatory pathology in experimental autoimmune encephalomyelitis. Am J Pathol 2006; 169: 584-598
244. Linker RA, Mäurer M, Gaupp S, Martini R, Holtmann B, Giess R, et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002; 8: 620-624
245. Micera A, Vigneti E, Aloe L. Changes of NGF presence in non-neuronal cells in response to experimental allergic encephalomyelitis in Lewis rats. Exp Neurol 1998; 154: 41-46
246. Villoslada P, Hauser SL, Bartke I, Unger J, Heald N, Rosenberg D, et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 2000; 191: 1799-1806
247. Azoulay D, Urshansky N, Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol 2008; 195: 186-193
248. Liguori M, Fera F, Patitucci A, Manna I, Condino F, Valentino P, et al. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis. Brain Res 2009; 1256: 123-128
249. Makar TK, Trisler D, Sura KT, Sultana S, Patel N, Bever CT. Brain derived neurotrophic factor treatment reduces inflammation and apoptosis in experimental allergic encephalomyelitis. J Neurol Sci 2008; 270: 70-76
250. DeLegge MH, Smoke A. Neurodegeneration and inflammation. Nutr Clin Pract 2008; 23: 35-41.
251. Dilger RN, Johnson RW. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J Leukoc Biol 2008; 84: 932-939
252. Godbout JP, Chen J, Abraham J, Richwine AF, Berg BM, Kelley KW, et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J 2005; 19: 1329-1331
253. Cotman CW. The role of neurotrophins in brain aging: a perspective in honor of Regino Perez-Polo. Neurochem Res 2005; 30: 877-881
254. Van Eldik LJ, Thompson WL, Ralay Ranaivo H, Behanna HA, Martin Watterson D. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function based and target-based discovery approaches. Int Rev Neurobiol 2007; 82: 277-296
255. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-α modulation for treatment of Alzheimer's disease: a 6-month pilot study. Med Gen Med 2006; 8: 25.
256. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflam 2008; 5: 2.
257. Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol 2008; 8: 27.
258. Griffin WS. Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflam 2008; 5: 3.
259. Fritschy JM, Grzanna R. Restoration of ascending noradrenergic projections by residual locus coeruleus neurons: compensatory response to neurotoxin-induced cell death in the adult rat brain. J Comp Neurol 1992; 321: 421-441
260. Arendt T, Brückner MK, Krell T, Pagliusi S, Kruska L, Heumann R. Degeneration of rat cholinergic basal forebrain neurons and reactive changes in nerve growth factor expression after chronic neurotoxic injury - II. Reactive expression of the nerve growth factor gene in astrocytes. Neuroscience 1995; 65: 647-659
261. Arendt T, Bigl V. Alzheimer's disease as a presumptive threshold phenomenon. Neurobiol Aging 1987; 8: 552-554
262. Arendt T, Marcova L, Bigl V, Brückner MK. Dendritic reorganisation in the basal forebrain under degenerative conditions and its defects in Alzheimer's disease. I. Dendritic organisation of the normal human basal forebrain. J Comp Neurol 1995; 351: 169-188
263. Arendt T, Brückner MK, Bigl V, Marcova L. Dendritic reorganisation in the basal forebrain under degenerative conditions and its defects in Alzheimer's disease. II. Ageing, Korsakoff's disease, Parkinson's disease, and Alzheimer's disease. J Comp Neurol 1995; 351: 189-222.
264. Ibata K, Sun Q, Turrigiano GG. Rapid synaptic scaling induced by changes in postsynaptic firing. Neuron 2008; 57: 819-826
265. Siegel M, Marder E, Abbott LF. Activity-dependent current distributions in model neurons. Proc Natl Acad Sci USA 1994; 91: 11308-11312
266. Mattson MP, Kater SB. Excitatory and inhibitory neurotransmitters in the generation and degeneration of hippocampal neuroarchitecture. Brain Res 1989; 478: 337-348
267. Bodary PF, Eitzman DT. Animal models of thrombosis. Curr Opin Hematol 2009; 16: 342-346
268. Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies - the need for new approaches. Cerebrovasc Dis 2004; 17: 153-166
269. Hao J, Ebendal T, Xu X, Wiesenfeld-Hallin Z, Eriksdotter Jonhagen M. Intracerebroventricular infusion of nerve growth factor induces pain like response in rats. Neurosci Lett 2000; 286: 208-212
270. Pizzo DP, Winkler J, Sidiqi I, Waite JJ, Thal LJ. Modulation of sensory inputs and ectopic presence of Schwann cells depend upon the route and duration of nerve growth factor administration. Exp Neurol 2002; 178: 91-103.
271. McTigue DM, Horner PJ, Stokes BT, Gage FH. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J Neurosci 1998; 18: 5354-5365
272. Massa SM, Xie Y, Yang T, Harrington AW, Kim ML, Yoon SO, et al. Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. J Neurosci 2006; 26: 5288-5300
273. Kraemer R, Hempstead BL. Neurotrophins: novel mediators of angiogenesis. Front Biosci 2003; 8: S1181-S6.
274. Chaldakov GN, Fiore M, Stankulov IS, Hristova M, Antonelli A, Manni L, et al. NGF, BDNF, leptin, and mast cells in human coronary atherosclerosis and metabolic syndrome. Arch Physiol Biochem 2001; 109: 357-360